A role for fragment-based drug design in developing novel lead compounds for central nervous system targets

Frontiers in Neurology

Volumn 6, Issue SEP, 2015, Pages

  Wasko, Michael J ^a   Pellegrene, Kendy A ^a   Madura, Jeffry D ^a   Surratt, Christopher K ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

CNS; Dopamine; Fragment based drug design; Structure; Target

Indexed keywords

ACETYLCHOLINESTERASE; BETA 2 ADRENERGIC RECEPTOR; BETA SECRETASE 1; CENTRAL NERVOUS SYSTEM AGENTS; COLLAGENASE 3; CYCLOOXYGENASE 2; DOPAMINE 3 RECEPTOR; ENZYME INHIBITOR; ETICLOPRIDE; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE A4 HYDROLASE; LIGAND; SEROTONIN; SEROTONIN TRANSPORTER;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FRAGMENT BASED DRUG DESIGN; HIGH THROUGHPUT SCREENING; MEDICINAL CHEMISTRY; NUCLEAR MAGNETIC RESONANCE; PARKINSON DISEASE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SITE DIRECTED MUTAGENESIS; VIRTUAL SCREENING;

EID: 84944730804     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00197     Document Type: Review

References (60)

1. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today (2012) 17:1088-102. doi: 10.1016/j.drudis.2012.05.007
2. Nicolaou KC. Advancing the drug discovery and development process. Angew Chemie (2014) 126:9280-92. doi:10.1002/ange.201404761
3. Miller G. Is pharma running out of brainy ideas? Science (2010) 329:502-4. doi:10.1126/science.329.5991.502
4. Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci (2012) 3:50-68. doi:10.1021/cn200100h
5. Immadisetty K, Geffert LM, Surratt CK, Madura JD. New design strategies for antidepressant drugs. Expert Opin Drug Discov (2013) 8:1399-414. doi:10.1517/17460441.2013.830102
6. Hubbard RE. Structure-based drug discovery and protein targets in the CNS. Neuropharmacology (2011) 60:7-23. doi:10.1016/j.neuropharm.2010.07.016
7. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis (2013) 36:437-49. doi:10.1007/s10545-013-9608-0
8. Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev (2013) 33:457-516. doi:10.1002/med.21252
9. Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem (2015) 58:2584-608. doi:10.1021/jm501535r
10. Joseph-McCarthy D, Campbell AJ, Kern G, Moustakas D. Fragment-based lead discovery and design. J Chem Inf Model (2014) 54:693-704. doi:10.1021/ci400731w
11. Mordalski S, Witek J, Smusz S, Rataj K, Bojarski AJ. Multiple conformational states in retrospective virtual screening-homology models vs. crystal structures: beta-2 adrenergic receptor case study. J Cheminform (2015) 7:13-21. doi:10.1186/s13321-015-0062-x
12. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, Schlessinger A, et al. Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 7:769-78. doi:10.1038/nchembio.662
13. Chien EYT, Liu W, Zhao Q, Katritch V, Han GW, Michael A, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2011) 330:1091-5. doi:10.1126/science.1197410.Structure
14. Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J Med Chem (2010) 53:5061-84. doi:10.1021/jm100112j
15. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol (2007) 3:466-79. doi:10.1038/nchembio.2007.17
16. Beresini MH, Liu Y, Dawes TD, Clark KR, Orren L, Schmidt S, et al. Small-molecule library subset screening as an aid for accelerating lead identification. J Biomol Screen (2014) 19:758-70. doi:10.1177/1087057114522515
17. Vyas VK, Ukawala RD, Ghate M, Chintha C. Homology modeling a fast tool for drug discovery: current perspectives. Indian J Pharm Sci (2012) 74:1-17. doi:10.4103/0250-474X.102537
18. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23:3-25. doi:10.1016/j.addr.2012.09.019
19. Owens J, Lipinski CA. Chris Lipinski discusses life and chemistry after the rule of five. Drug Discov Today (2003) 8:12-6. doi:10.1016/S1359-6446(02)02556-4
20. Boyd SM, De Kloe GE. Fragment library design: efficiently hunting drugs in chemical space. Drug Discov Today Technol (2010) 7:e173-80. doi:10.1016/j.ddtec.2010.11.010
21. Hajduk PJ. Fragment-based drug design: how big is too big? J Med Chem (2006) 49:6972-6. doi:10.1021/jm060511h
22. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem (1985) 28:849-57. doi:10.1021/jm00145a002
23. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins (1991) 11:29-34. doi:10.1002/prot.340110104
24. Caflisch A, Miranker A, Karplus M. Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J Med Chem (1993) 36:2142-67. doi:10.1021/jm00067a013
25. Böhm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des (1992) 6:61-78. doi:10.1007/BF00124387
26. Gillet V, Johnson AP, Mata P, Sike S, Williams P. SPROUT: a program for structure generation. J Comput Aided Mol Des (1993) 7:127-53. doi:10.1007/BF00126441
27. Verdonk ML, Cole JC, Taylor R. SuperStar: a knowledge-based approach for identifying interaction sites in proteins. J Mol Biol (1999) 289:1093-108. doi:10.1006/jmbi.1999.2809
28. Carlson HA, Masukawa KM, Rubins K, Bushman FD, Jorgensen WL, Lins RD, et al. Developing a dynamic pharmacophore model for HIV-1 integrase. J Med Chem (2000) 43:2100-14. doi:10.1021/jm990322h
29. Congreve M, Carr R, Murray C, Jhoti H. A "rule of three" for fragment-based lead discovery? Drug Discov Today (2003) 8:876-7. doi:10.1016/S1359-6446(03)02831-9
30. Köster H, Craan T, Brass S, Herhaus C, Zentgraf M, Neumann L, et al. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. J Med Chem (2011) 54:7784-96. doi:10.1021/jm200642w
31. Jhoti H, Williams G, Rees DC, Murray CW. The "rule of three" for fragment-based drug discovery: where are we now? Nat Rev Drug Discov (2013) 12:644-5. doi:10.1038/nrd3926-c1
32. Hopkins AL, Keserü GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov (2014) 13:105-21. doi:10.1038/nrd4163
33. Hajduk PJ, Galloway WRJD, Spring DR. Drug discovery: a question of library design. Nature (2011) 470:42-3. doi:10.1038/470042a
34. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov (2007) 6:211-9. doi:10.1038/nrd2220
35. Dahlin JL, Walters MA. The essential roles of chemistry in high-throughput screening triage. Future Med Chem (2014) 6:1265-90. doi:10.4155/fmc.14.60
36. Vass M, Schmidt É, Horti F, Keseru GM. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. Eur J Med Chem (2014) 77:38-46. doi:10.1016/j.ejmech.2014.02.034
37. Chen IJ, Hubbard RE. Lessons for fragment library design: analysis of output from multiple screening campaigns. J Comput Aided Mol Des (2009) 23:603-20. doi:10.1007/s10822-009-9280-5
38. Morley AD, Pugliese A, Birchall K, Bower J, Brennan P, Brown N, et al. Fragment-based hit identification: thinking in 3D. Drug Discov Today (2013) 18:1221-7. doi:10.1016/j.drudis.2013.07.011
39. De Graaf C, Kooistra AJ, Vischer HF, Katritch V, Kuijer M, Shiroishi M, et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H 1 receptor. J Med Chem (2011) 54:8195-206. doi:10.1021/jm2011589
40. Chen D, Ranganathan A, IJzerman AP, Siegal G, Carlsson J. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. J Chem Inf Model (2013) 53:2701-14. doi:10.1021/ci4003156
41. Schultes S, Kooistra AJ, Vischer HF, Nijmeijer S, Haaksma EEJ, Leurs R, et al. Combinatorial consensus scoring for ligand-based virtual fragment screening: a comparative case study for serotonin 5-HT 3 A, histamine H 1, and histamine H 4 receptors. J Chem Inf Model (2015) 55:1030-44. doi:10.1021/ci500694c
42. Verheij MHP, de Graaf C, de Kloe GE, Nijmeijer S, Vischer HF, Smits RA, et al. Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A. Bioorg Med Chem Lett (2011) 21:5460-4. doi:10.1016/j.bmcl.2011.06.123
43. Shang E, Yuan Y, Chen X, Liu Y, Pei J, Lai L. De novo design of multitarget ligands with an iterative fragment-growing strategy. J Chem Inf Model (2014) 54:1235-41. doi:10.1021/ci500021v
44. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol (2014) 54:165-84. doi:10.1146/annurev-pharmtox-010611-134525
45. Vass M, Agai-Csongor E, Horti F, Keseru GM. Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors. ACS Med Chem Lett (2014) 5:1010-4. doi:10.1021/ml500201u
46. Lanz J, Riedl R. merging allosteric and active site binding motifs: de novo generation of target selectivity and potency via natural-product-derived fragments. ChemMedChem (2015) 10:451-4. doi:10.1002/cmdc.201402478
47. Kortagere S, Fontana ACK, Renée Rose D, Mortensen OV. Identification of an allosteric modulator of the serotonin transporter with novel mechanism of action. Neuropharmacology (2013) 72:282-90. doi:10.1016/j.neuropharm.2013.04.026
48. Goyal M, Dhanjal JK, Goyal S, Tyagi C, Hamid R, Grover A. Development of dual inhibitors against Alzheimer's disease using fragment-based QSAR and molecular docking. Biomed Res Int (2014) 2014:979606. doi:10.1155/2014/979606
49. Roughley SD, Jordan AM. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J Med Chem (2011) 54:3451-79. doi:10.1021/jm200187y
50. Stewart KD, Shiroda M, James CA. Drug Guru: a computer software program for drug design using medicinal chemistry rules. Bioorg Med Chem (2006) 14:7011-22. doi:10.1016/j.bmc.2006.06.024
51. Segall M, Champness E, Leeding C, Lilien R, Mettu R, Stevens B. Applying medicinal chemistry transformations and multiparameter optimization to guide the search for high-quality leads and candidates. J Chem Inf Model (2011) 51:2967-76. doi:10.1021/ci2003208
52. Weininger D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Comput Sci (1988) 28:31-6. doi:10.1021/ci00057a005
53. StarDrop. StarDrop, Version 5.0. Cambridge: Optibrium, Ltd (2011).
54. Durrant JD, Amaro RE, McCammon JA. AutoGrow: a novel algorithm for protein inhibitor design. Chem Biol Drug Des (2009) 73:168-78. doi:10.1111/j.1747-0285.2008.00761.x
55. Trott O, Olson A. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem (2010) 31:455-61. doi:10.1002/jcc.21334.AutoDock
56. Durrant JD, Lindert S, McCammon JA. AutoGrow 3.0: an improved algorithm for chemically tractable, semi-automated protein inhibitor design1. J Mol Graph Model (2013) 44:104-12. doi:10.1016/jjmgm.2013.05.006
57. Maass P, Schulz-Gasch T, Stahl M, Rarey M. Recore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations. J Chem Inf Model (2007) 47:390-99. doi:10.1021/ci060094h
58. Lessel U, Wellenzohn B, Lilienthal M, Claussen H. Searching fragment spaces with feature trees. J Chem Inf Model (2009) 49:270-79. doi:10.1021/ci800272a
59. Boehm M, Wu TY, Haussen H, Lemmen C. Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces. J Med Chem (2008) 51:2468-80. doi:10.1021/jm0707727
60. Cherezov V, Rosenbaum DM, Hanson MA, Søren GF, Thian FS, Kobilka TS, et al. High resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 318:1258-65. doi:10.1126/science.1150577.High